SCHEMBL25867761

SCHEMBL25867761

COc1nc(Cl)cc(NC(C)C)n1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 1/20 0.39
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ GAA P10253 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ CDK2 P24941 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ HRH4 Q9H3N8 3/20 0.33
▸ KCNH3 Q9ULD8 2/20 0.32
▸ PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25083886 0.80 NPC1 (0.47) TRPM8KMT2ASMN1; SMN2ALDH1A1TDP1
SCHEMBL26877797 0.80 TRPM8 (0.44) TRPM8MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL26698986 0.79 MAPT (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL4648295 0.78 MAPT (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL12127970 0.77 TRPM8 (0.39) TRPM8MEN1KMT2AALDH1A1GAA
SCHEMBL1748325 0.77 GAA (0.48) TRPM8MEN1KMT2AALDH1A1GAA
SCHEMBL232399 0.76 MAPT (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL9536488 0.76 FPR2 (0.40) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL9493382 0.76 GAA (0.52) TRPM8MEN1KMT2AALDH1A1GAA
SCHEMBL12411085 0.76 MEN1 (0.44) TRPM8MEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 — — US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 — — US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A TRPM8 1438/4885MEN1 3647/4885KMT2A 4789/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A TRPM8 2144/4885MEN1 4131/4885KMT2A 3629/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R TRPM8 713/4885MEN1 641/4885KMT2A 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback